James William Burns sold $142k of AGIO
Chief Legal Officer at AGIOS PHARMACEUTICALS, INC.. 4,005 shares at an average of $35.54, traded Mar 3, 2025, filed Mar 4, 2025.
Score components
- +15RoleOfficer
- +11Trade size$142k at market
- +5Share of holdings soldSold 20% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001439222-25-000021, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 1, 2025 | MOption exercise Common stock10b5-1 | +3,833 | $0.00 | $0 | 19,787 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common stock10b5-1 | -1,137 | $35.54 | $40k | 18,650 | Mar 4, 2025 |
| Mar 1, 2025 | MOption exercise Common stock10b5-1 | +4,000 | $0.00 | $0 | 22,650 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common stock10b5-1 | -1,187 | $35.54 | $42k | 21,463 | Mar 4, 2025 |
| Mar 1, 2025 | MOption exercise Common stock10b5-1 | +5,667 | $0.00 | $0 | 27,130 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common stock10b5-1 | -1,681 | $35.54 | $60k | 25,449 | Mar 4, 2025 |
| Mar 1, 2025 | AGrant or award Restricted stock unitsderivative10b5-1 | +12,000 | $0.00 | $0 | 12,000 | Mar 4, 2025 |
| Mar 1, 2025 | AGrant or award Restricted stock unitsderivative10b5-1 | +11,759 | $0.00 | $0 | 11,759 | Mar 4, 2025 |
| Mar 1, 2025 | AGrant or award Stock options (right to buy)derivative10b5-1 | +43,500 | $0.00 | $0 | 43,500 | Mar 4, 2025 |
| Mar 1, 2025 | MOption exercise Restricted stock unitsderivative10b5-1 | -3,833 | $0.00 | $0 | 0 | Mar 4, 2025 |
| Mar 1, 2025 | MOption exercise Restricted stock unitsderivative10b5-1 | -4,000 | $0.00 | $0 | 4,000 | Mar 4, 2025 |
| Mar 1, 2025 | MOption exercise Restricted stock unitsderivative10b5-1 | -5,667 | $0.00 | $0 | 11,333 | Mar 4, 2025 |
Related signals
Other insiders at AGIOS PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | AGIOS PHARMACEUTICALS, INC. | Brian Goff Chief Executive Officer | $627k 18,700 shares | -16% | |
| 5Weak | AGIOS PHARMACEUTICALS, INC. | Tsveta Milanova Chief Commercial Officer | $93k 2,770 shares | -10% | |
| 9Weak | AGIOS PHARMACEUTICALS, INC. | Cecilia Jones Chief Financial Officer | $60k 1,780 shares | -6% | |
| 5Weak | AGIOS PHARMACEUTICALS, INC. | Sarah Gheuens Chief Medical Officer | $98k 2,909 shares | -5% | |
| 5Weak | AGIOS PHARMACEUTICALS, INC. | James William Burns Chief Legal Officer | $94k 2,799 shares | -9% | |
| 0Weak | AGIOS PHARMACEUTICALS, INC. | Jacqualyn A Fouse director | $194k 7,497 shares | -5% | |
| 12Weak | AGIOS PHARMACEUTICALS, INC. | Theodore James Washburn Jr. Principal Accounting Officer | $59k 1,655 shares | -26% | |
| 6Weak | AGIOS PHARMACEUTICALS, INC. | Sarah Gheuens Chief Medical Officer | $142k 4,005 shares | -8% | |
| 27Weak | AGIOS PHARMACEUTICALS, INC. | Brian Goff Chief Executive Officer | $460k 12,947 shares | -15% | |
| 2Weak | AGIOS PHARMACEUTICALS, INC. | Tsveta Milanova Chief Commercial Officer | $60k 1,681 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.